CEO William Meury was paid $32,085,952 in fiscal year 2025, the 92nd percentile of its disclosed peer group (SEC filing 0000879169-26-000031 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$32,085,952 William Meury total, FY2025 | 92nd CEO pay percentile vs peers | 110.47:1 CEO-to-median pay ratio | 83.86% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
INCY's next annual pay disclosure, estimated April 27, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| William Meury | $647,260 | $0 | $27,509,657 | $2,573,998 | $1,300,000 | $0 | $55,037 | $32,085,952 |
| Chief Executive Officer | ||||||||
| Mohamed Issa | 690,411 | 1,000,000 | 7,870,118 | 450,983 | 533,610 | 0 | 47,660 | 10,592,782 |
| Executive Vice President and Head of U.S. Commercial | ||||||||
| Pablo Cagnoni | 966,516 | 0 | 4,952,378 | 1,815,159 | 1,007,027 | 0 | 97,881 | 8,838,961 |
| President and Global Head of Research and Development | ||||||||
| Herve Hoppenot | 1,392,499 | 0 | 1,971,975 | 1,694,034 | 1,026,072 | 0 | 295,945 | 6,380,525 |
| Former President and Chief Executive Officer | ||||||||
| Steven Stein | 835,067 | 0 | 3,466,675 | 1,270,592 | 696,054 | 0 | 35,784 | 6,304,172 |
| Executive Vice President, Chief Medical Officer and Head of Late-stage Development | ||||||||
| Christiana Stamoulis | 520,839 | 0 | 3,136,468 | 1,149,588 | 0 | 0 | 129,655 | 4,936,550 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
| Thomas Tray | 358,189 | 0 | 305,897 | 154,623 | 149,423 | 0 | 22,236 | 990,368 |
| Vice President, Chief Accounting Officer and Principal Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| William Meury | $32,085,952 | — | — | — |
| Mohamed Issa | 10,592,782 | — | — | — |
| Pablo Cagnoni | 8,838,961 | 7,904,299 | — | ↑ +934,662 |
| Herve Hoppenot | 6,380,525 | 17,459,546 | 16,659,526 | ↓ −11,079,021 |
| Steven Stein | 6,304,172 | 5,979,828 | — | ↑ +324,344 |
| Christiana Stamoulis | 4,936,550 | 5,397,757 | — | ↓ −461,207 |
| Thomas Tray | 990,368 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read INCYTE CORP's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper INCY reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the INCYTE CORP Peer Teardown Report
$32,085,952 William Meury total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 19, 2026 · Source: 0000879169-26-000031 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for INCY
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order INCY
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses INCY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INCY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the INCYTE CORP Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Christiana Stamoulis | Executive | $4,936,550 |
| Mohamed Issa | EVP | $10,592,782 |
| Pablo Cagnoni | President | $8,838,961 |
| Steven Stein | EVP | $6,304,172 |
| Thomas Tray | Executive | $990,368 |
| William Meury | CEO | $32,085,952 |
| Herve Hoppenot | Executive | $6,380,525 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Edmund P. Harrigan | Independent Director | $539,638 |
| Jacqualyn A. Fouse | Independent Director | $524,638 |
| Jean-Jacques Bienaimé | Independent Director | $536,138 |
| Julian C. Baker | Independent Director | $573,138 |
| Katherine A. High | Independent Director | $511,138 |
| Otis W. Brawley | Independent Director | $511,138 |
| Paul J. Clancy | Independent Director | $538,138 |
| Susanne Schaffert | Independent Director | $523,138 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Suketu Upadhyay | EVP & Chief Financial Officer | 2026-05-04 | A | 13,171 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Suketu Upadhyay | EVP & Chief Financial Officer | 2026-05-04 | A | 38,429 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suketu Upadhyay | EVP & Chief Financial Officer | 2026-05-04 | A | 26,343 | 0 | 0 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-05-06 | A | 44,124 | 0 | 0 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-05-06 | A | 31,517 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-05-19 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-05-19 | D | 15,000 | 95 | 1,423,950 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-05-19 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-05-26 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-05-26 | D | 13,059 | 97 | 1,268,029 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-05-26 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-05-26 | D | 2,051 | 97 | 199,665 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-06-01 | D | 25,469 | 96 | 2,434,582 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-06-04 | A | 2,639 | 84 | 221,227 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-06-04 | D | 2,639 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-06-04 | D | 2,639 | 100 | 263,900 | Common | Form 4 ↗ |
| Otis W. Brawley | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Otis W. Brawley | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Katherine A. High | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine A. High | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacqualyn A. Fouse | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Jacqualyn A. Fouse | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-30 | A | 400 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-30 | A | 400 | 0 | 0 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-06-30 | A | 252 | 113 | 28,567 | Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-06-30 | A | 255 | 113 | 28,907 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-02 | D | 2,177 | 117 | 254,404 | Common | Form 4 ↗ |
| William Meury | Director | 2026-07-02 | D | 4,779 | 117 | 558,474 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-02 | D | 477 | 117 | 55,742 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-02 | D | 350 | 117 | 40,901 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-14 | D | 21,830 | 115 | 2,507,830 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-14 | D | 692 | 115 | 79,497 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-14 | D | 437 | 115 | 50,203 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-14 | D | 17,969 | 115 | 2,064,279 | Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-15 | D | 1,099 | 115 | 126,484 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-15 | D | 3,088 | 115 | 355,398 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-15 | D | 28,237 | 113 | 3,192,193 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-15 | D | 1,512 | 115 | 174,016 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-15 | D | 4,950 | 115 | 569,696 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-15 | D | 1,098 | 115 | 126,369 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-16 | A | 33,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | A | 19,643 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Meury | Director | 2026-07-16 | A | 80,421 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Hoffman | EVP & General Counsel | 2026-07-16 | A | 7,395 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Hoffman | EVP & General Counsel | 2026-07-16 | A | 18,487 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-07-16 | A | 18,487 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | D | 1,093 | 115 | 125,706 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-16 | A | 13,403 | 0 | 0 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-16 | A | 57,861 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | A | 24,496 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-16 | A | 25,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | A | 9,798 | 0 | 0 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | D | 1,877 | 115 | 215,348 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-16 | A | 4,079 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-16 | A | 2,834 | 0 | 0 | Common | Form 4 ↗ |
| William Meury | Director | 2026-07-16 | A | 26,807 | 0 | 0 | Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-07-16 | A | 7,395 | 0 | 0 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-16 | A | 14,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Meury | Director | 2026-07-16 | A | 77,148 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Hoffman | EVP & General Counsel | 2026-07-16 | A | 31,923 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-07-16 | A | 21,548 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | A | 33,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | A | 42,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-07-16 | A | 4,991 | 0 | 0 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-16 | A | 5,916 | 0 | 0 | Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-07-16 | A | 31,923 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-07-16 | A | 12,479 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | A | 7,857 | 0 | 0 | Common | Form 4 ↗ |
| Lee Heeson | EVP, Head of Incyte Intl | 2026-07-23 | A | 15,423 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lee Heeson | EVP, Head of Incyte Intl | 2026-07-23 | A | 13,498 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael James Morrissey | EVP, Head of Tech. Operations | 2026-07-23 | A | 6,426 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael James Morrissey | EVP, Head of Tech. Operations | 2026-07-23 | A | 8,999 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-31 | — | 3,696 | — | — | 1 insider, 4 accrual rows | ||
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,293 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,623 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 9,459 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 3,148 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,709 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,293 | 119 | 273,807 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 326 | 122 | 39,671 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 6,171 | 119 | 737,003 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,187 | 119 | 261,281 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 5,332 | 119 | 636,747 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 14,661 | 119 | 1,751,403 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 1,643 | 81 | 132,262 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,864 | 78 | 222,447 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,623 | 75 | 196,148 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 9,459 | 72 | 683,602 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,072 | 72 | 149,039 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 3,148 | 69 | 216,016 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,284 | 64 | 146,747 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,918 | 61 | 178,523 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-31 | D | 15,888 | 120 | 1,901,794 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 1,643 | 120 | 196,355 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 4,695 | 119 | 560,536 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 1,642 | 119 | 196,022 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,709 | 62 | 167,308 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,623 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 3,023 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,864 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 85 | 122 | 10,386 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,864 | 119 | 341,962 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 326 | 105 | 34,370 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 85 | 106 | 9,050 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,293 | 91 | 207,654 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 1,642 | 85 | 139,586 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,623 | 84 | 219,230 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 3,023 | 83 | 251,514 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-03 | D | 6,055 | 120 | 729,204 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-03 | A | 6,055 | 105 | 638,379 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-03 | D | 6,055 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-05 | D | 2,207 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-05 | D | 2,207 | 124 | 273,646 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-05 | A | 2,207 | 106 | 234,979 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-08-05 | D | 10,640 | 123 | 1,305,422 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-08-12 | D | 10,803 | 120 | 1,296,792 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-08-19 | D | 10,801 | 126 | 1,356,174 | Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-08-25 | D | 504 | 130 | 65,379 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 6,477 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 4,551 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 2,957 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 13,985 | 120 | 1,685,053 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 9,233 | 121 | 1,112,577 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 6,477 | 64 | 416,147 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 4,551 | 61 | 278,430 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 9,233 | 72 | 664,130 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 9,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 2,957 | 62 | 182,624 | Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-09-22 | D | 920 | 127 | 116,776 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-09-30 | A | 203 | 121 | 24,634 | Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-09-30 | A | 206 | 121 | 24,998 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-30 | A | 322 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-30 | A | 322 | 0 | 0 | Common | Form 4 ↗ |
| Lee Heeson | EVP, Head of Incyte Intl | 2026-10-01 | D | 463 | 117 | 54,236 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-15 | — | 2,642 | — | — | 1 insider, 4 accrual rows | ||
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | D | 2,642 | 113 | 297,780 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 925 | 64 | 59,431 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 455 | 61 | 27,837 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 423 | 62 | 26,124 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 839 | 72 | 60,349 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Suketu Upadhyay | EVP & Chief Financial Officer | 2026-05-04 | A | 13,171 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Suketu Upadhyay | EVP & Chief Financial Officer | 2026-05-04 | A | 38,429 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suketu Upadhyay | EVP & Chief Financial Officer | 2026-05-04 | A | 26,343 | 0 | 0 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-05-06 | A | 44,124 | 0 | 0 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-05-06 | A | 31,517 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-08 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-05-19 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-05-19 | D | 15,000 | 95 | 1,423,950 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-05-19 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-05-26 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-05-26 | D | 13,059 | 97 | 1,268,029 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-05-26 | A | 15,000 | 85 | 1,267,950 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-05-26 | D | 2,051 | 97 | 199,665 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-06-01 | D | 25,469 | 96 | 2,434,582 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-06-04 | A | 2,639 | 84 | 221,227 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-06-04 | D | 2,639 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-06-04 | D | 2,639 | 100 | 263,900 | Common | Form 4 ↗ |
| Otis W. Brawley | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Otis W. Brawley | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Katherine A. High | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine A. High | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacqualyn A. Fouse | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 1,642 | 0 | 0 | Common | Form 4 ↗ |
| Jacqualyn A. Fouse | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-08 | A | 6,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-30 | A | 400 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-30 | A | 400 | 0 | 0 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-06-30 | A | 252 | 113 | 28,567 | Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-06-30 | A | 255 | 113 | 28,907 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-02 | D | 2,177 | 117 | 254,404 | Common | Form 4 ↗ |
| William Meury | Director | 2026-07-02 | D | 4,779 | 117 | 558,474 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-02 | D | 477 | 117 | 55,742 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-02 | D | 350 | 117 | 40,901 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-14 | D | 21,830 | 115 | 2,507,830 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-14 | D | 692 | 115 | 79,497 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-14 | D | 437 | 115 | 50,203 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-14 | D | 17,969 | 115 | 2,064,279 | Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-15 | D | 1,099 | 115 | 126,484 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-15 | D | 3,088 | 115 | 355,398 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-15 | D | 28,237 | 113 | 3,192,193 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-15 | D | 1,512 | 115 | 174,016 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-15 | D | 4,950 | 115 | 569,696 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-15 | D | 1,098 | 115 | 126,369 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-16 | A | 33,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | A | 19,643 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Meury | Director | 2026-07-16 | A | 80,421 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Hoffman | EVP & General Counsel | 2026-07-16 | A | 7,395 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Hoffman | EVP & General Counsel | 2026-07-16 | A | 18,487 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-07-16 | A | 18,487 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | D | 1,093 | 115 | 125,706 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-16 | A | 13,403 | 0 | 0 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-16 | A | 57,861 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | A | 24,496 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-16 | A | 25,538 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | A | 9,798 | 0 | 0 | Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | D | 1,877 | 115 | 215,348 | Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-16 | A | 4,079 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Tray | Principal Accounting Officer | 2026-07-16 | A | 2,834 | 0 | 0 | Common | Form 4 ↗ |
| William Meury | Director | 2026-07-16 | A | 26,807 | 0 | 0 | Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-07-16 | A | 7,395 | 0 | 0 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-16 | A | 14,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Meury | Director | 2026-07-16 | A | 77,148 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Hoffman | EVP & General Counsel | 2026-07-16 | A | 31,923 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-07-16 | A | 21,548 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | A | 33,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Stein | CMO & Head of Late-Stage Dev. | 2026-07-16 | A | 42,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-07-16 | A | 4,991 | 0 | 0 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-16 | A | 5,916 | 0 | 0 | Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-07-16 | A | 31,923 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-07-16 | A | 12,479 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mohamed Issa | EVP, Head of U.S. Commercial | 2026-07-16 | A | 7,857 | 0 | 0 | Common | Form 4 ↗ |
| Lee Heeson | EVP, Head of Incyte Intl | 2026-07-23 | A | 15,423 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lee Heeson | EVP, Head of Incyte Intl | 2026-07-23 | A | 13,498 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael James Morrissey | EVP, Head of Tech. Operations | 2026-07-23 | A | 6,426 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael James Morrissey | EVP, Head of Tech. Operations | 2026-07-23 | A | 8,999 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 85 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 326 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,293 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 1,642 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,623 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 9,459 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 3,148 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,709 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,293 | 119 | 273,807 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 326 | 122 | 39,671 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 6,171 | 119 | 737,003 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,187 | 119 | 261,281 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 5,332 | 119 | 636,747 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 14,661 | 119 | 1,751,403 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 1,643 | 81 | 132,262 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,864 | 78 | 222,447 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,623 | 75 | 196,148 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 9,459 | 72 | 683,602 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,072 | 72 | 149,039 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 3,148 | 69 | 216,016 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,284 | 64 | 146,747 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,918 | 61 | 178,523 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-07-31 | D | 15,888 | 120 | 1,901,794 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 1,643 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 1,643 | 120 | 196,355 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 4,695 | 119 | 560,536 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 1,642 | 119 | 196,022 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,709 | 62 | 167,308 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,623 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 3,023 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,864 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 85 | 122 | 10,386 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | D | 2,864 | 119 | 341,962 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 326 | 105 | 34,370 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 85 | 106 | 9,050 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,293 | 91 | 207,654 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 1,642 | 85 | 139,586 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 2,623 | 84 | 219,230 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-07-31 | A | 3,023 | 83 | 251,514 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-03 | D | 6,055 | 120 | 729,204 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-03 | A | 6,055 | 105 | 638,379 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-03 | D | 6,055 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-05 | D | 2,207 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-05 | D | 2,207 | 124 | 273,646 | Common | Form 4 ↗ |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 2026-08-05 | A | 2,207 | 106 | 234,979 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-08-05 | D | 10,640 | 123 | 1,305,422 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-08-12 | D | 10,803 | 120 | 1,296,792 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-08-19 | D | 10,801 | 126 | 1,356,174 | Common | Form 4 ↗ |
| Ramitpal K. Basi | EVP, Human Resources | 2026-08-25 | D | 504 | 130 | 65,379 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 6,477 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 4,551 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 2,957 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 13,985 | 120 | 1,685,053 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 9,233 | 121 | 1,112,577 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 6,477 | 64 | 416,147 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 4,551 | 61 | 278,430 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 9,233 | 72 | 664,130 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | D | 9,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-09-15 | A | 2,957 | 62 | 182,624 | Common | Form 4 ↗ |
| David H. Gardner | EVP, Chief Strategy Officer | 2026-09-22 | D | 920 | 127 | 116,776 | Common | Form 4 ↗ |
| Paul J. Clancy | Director | 2026-09-30 | A | 203 | 121 | 24,634 | Common | Form 4 ↗ |
| Edmund P. Harrigan | Director | 2026-09-30 | A | 206 | 121 | 24,998 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-30 | A | 322 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-30 | A | 322 | 0 | 0 | Common | Form 4 ↗ |
| Lee Heeson | EVP, Head of Incyte Intl | 2026-10-01 | D | 463 | 117 | 54,236 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | D | 925 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | D | 455 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | D | 423 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | D | 839 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | D | 2,642 | 113 | 297,780 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 925 | 64 | 59,431 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 455 | 61 | 27,837 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 423 | 62 | 26,124 | Common | Form 4 ↗ |
| Pablo Cagnoni | President, Global Head of R&D | 2026-10-15 | A | 839 | 72 | 60,349 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| William Meury | PSU | 2025-07-02 | 54,152 | 108,303 | — | 216,606 | $9,276,152 |
| Thomas Tray | PSU | 2025-07-15 | — | 4,482 | — | 13 | 305,897 |
| Pablo Cagnoni | OPTION | 2025-07-15 | — | — | 39,471 | — | 901,981 |
| Mohamed Issa | PSU | 2025-07-15 | 10,962 | 21,923 | — | 43,846 | 1,877,705 |
| Mohamed Issa | PSU | 2025-07-15 | — | 8,769 | — | 13 | 598,484 |
| Mohamed Issa | RSU | 2025-01-06 | — | — | 48,671 | — | 3,499,932 |
| Christiana Stamoulis | PSU | 2025-07-15 | — | 11,107 | — | 13 | 758,053 |
| Steven Stein | PSU | 2025-07-15 | 15,346 | 30,692 | — | 61,384 | 2,628,770 |
| Christiana Stamoulis | PSU | 2025-07-15 | 13,885 | 27,769 | — | 55,538 | 2,378,415 |
| Hervé Hoppenot | OPTION | 2025-06-26 | — | — | 11 | — | 428,997 |
| Hervé Hoppenot | OPTION | 2025-01-17 | — | — | 10 | — | 1,258,171 |
| Hervé Hoppenot | PSU | 2025-06-26 | — | 6,016 | — | 13 | 425,993 |
| Hervé Hoppenot | PSU | 2025-06-26 | 9,025 | 18,050 | — | 36,100 | 1,545,982 |
| Mohamed Issa | PSU | 2025-06-30 | — | 27,812 | — | 14 | 1,893,997 |
| Steven Stein | PSU | 2025-07-15 | — | 12,277 | — | 13 | 837,905 |
| Mohamed Issa | OPTION | 2025-07-15 | — | — | 19,735 | — | 450,983 |
| Thomas Tray | OPTION | 2025-01-17 | — | — | 3,432 | — | 77,790 |
| William Meury | PSU | 2025-07-02 | — | 125,000 | — | 500,000 | 15,772,500 |
| Christiana Stamoulis | OPTION | 2025-07-15 | — | — | 24,998 | — | 571,250 |
| Pablo Cagnoni | PSU | 2025-07-15 | — | 17,538 | — | 13 | 1,196,969 |
| William Meury | RSU | 2025-07-02 | — | — | 36,101 | — | 2,461,005 |
| Pablo Cagnoni | PSU | 2025-07-15 | 21,923 | 43,846 | — | 87,692 | 3,755,409 |
| Steven Stein | OPTION | 2025-01-17 | — | — | 28,202 | — | 639,221 |
| William Meury | OPTION | 2025-06-26 | — | — | 110,630 | — | 2,573,998 |
| Thomas Tray | OPTION | 2025-07-15 | — | — | 3,362 | — | 76,833 |
| Christiana Stamoulis | OPTION | 2025-01-17 | — | — | 25,516 | — | 578,338 |
| Steven Stein | OPTION | 2025-07-15 | — | — | 27,629 | — | 631,371 |
| Pablo Cagnoni | OPTION | 2025-01-17 | — | — | 40,289 | — | 913,178 |
| Hervé Hoppenot | OPTION | 2016-01-07 | — | — | 15 | — | 6,866 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| William Meury | $2,461,005 | $25,048,652 | $2,573,998 | 83.3% |
| Thomas Tray | 0 | 305,897 | 154,623 | 66.4% |
| Pablo Cagnoni | 0 | 4,952,378 | 1,815,159 | 73.2% |
| Mohamed Issa | 3,499,932 | 4,370,186 | 450,983 | 52.5% |
| Christiana Stamoulis | 0 | 3,136,468 | 1,149,588 | 73.2% |
| Steven Stein | 0 | 3,466,675 | 1,270,592 | 73.2% |
| Hervé Hoppenot | 0 | 1,971,975 | 1,694,034 | 53.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Hoppenot | Option | 11,942 | 77.67 | — |
| Pablo Cagnoni | RSU | 14,889 | — | 1,470,587 |
| Hoppenot | RSU | 107,960 | — | 10,663,209 |
| Hoppenot | RSU | 249,086 | — | 24,602,225 |
| Pablo Cagnoni | PSU | 229,661 | — | 22,683,617 |
| Pablo Cagnoni | RSU | 192,400 | — | 19,003,348 |
| William Meury | RSU | 125,000 | — | 12,346,250 |
| Hoppenot | RSU | 123,076 | — | 12,156,217 |
| Pablo Cagnoni | RSU | 117,643 | — | 11,619,599 |
| William Meury | RSU | 108,303 | — | 10,697,087 |
| Steven Stein | RSU | 99,269 | — | 9,804,799 |
| Hoppenot | PSU | 70,643 | — | 6,977,409 |
| Pablo Cagnoni | RSU | 49,627 | — | 4,901,659 |
| Mohamed Issa | RSU | 48,671 | — | 4,807,235 |
| Pablo Cagnoni | RSU | 43,846 | — | 4,330,669 |
| William Meury | RSU | 36,101 | — | 3,565,696 |
| Pablo Cagnoni | RSU | 17,538 | — | 1,732,228 |
| Steven Stein | RSU | 34,739 | — | 3,431,171 |
| Steven Stein | PSU | 34,203 | — | 3,378,230 |
| Steven Stein | RSU | 33,838 | — | 3,342,179 |
| Steven Stein | RSU | 30,692 | — | 3,031,449 |
| Pablo Cagnoni | RSU | 4,834 | — | 477,454 |
| Hoppenot | RSU | 29,468 | — | 2,910,554 |
| Mohamed Issa | RSU | 27,812 | — | 2,746,991 |
| Pablo Cagnoni | RSU | 24,170 | — | 2,387,271 |
| Mohamed Issa | RSU | 21,923 | — | 2,165,335 |
| Hoppenot | Option | 12,608 | 83.2 | — |
| Hoppenot | RSU | 20,684 | — | 2,042,959 |
| Hoppenot | RSU | 18,050 | — | 1,782,799 |
| Thomas Tray | PSU | 15,166 | — | 1,497,945 |
| Hoppenot | RSU | 14,475 | — | 1,429,696 |
| Steven Stein | RSU | 12,277 | — | 1,212,599 |
| Steven Stein | RSU | 10,422 | — | 1,029,381 |
| Mohamed Issa | RSU | 8,769 | — | 866,114 |
| Steven Stein | RSU | 6,768 | — | 668,475 |
| Hoppenot | RSU | 6,016 | — | 594,200 |
| Thomas Tray | RSU | 1,038 | — | 102,523 |
| Steven Stein | RSU | 4,736 | — | 467,775 |
| Thomas Tray | RSU | 3,805 | — | 375,820 |
| Thomas Tray | RSU | 4,482 | — | 442,687 |
| Thomas Tray | RSU | 3,008 | — | 297,100 |
| Thomas Tray | RSU | 2,833 | — | 279,815 |
| William Meury | Option | 110,630 | 70.81 | — |
| Hoppenot | Option | 35,849 | 61.76 | — |
| Hoppenot | Option | 38,621 | 61.18 | — |
| Hoppenot | Option | 39,519 | 64.25 | — |
| Hoppenot | Option | 35,851 | 71.93 | — |
| Hoppenot | Option | 18,438 | 70.81 | — |
| Pablo Cagnoni | Option | 8,026 | 61.76 | — |
| Pablo Cagnoni | Option | 8,647 | 61.18 | — |
| Pablo Cagnoni | Option | 28,683 | 64.25 | — |
| Pablo Cagnoni | Option | 26,021 | 71.93 | — |
| Pablo Cagnoni | Option | 39,471 | 68.25 | — |
| Mohamed Issa | Option | 19,735 | 68.25 | — |
| Steven Stein | Option | 3,743 | 77.67 | — |
| Steven Stein | Option | 3,952 | 83.2 | — |
| Steven Stein | Option | 11,236 | 61.76 | — |
| Steven Stein | Option | 12,105 | 61.18 | — |
| Steven Stein | Option | 20,078 | 64.25 | — |
| Steven Stein | Option | 18,215 | 71.93 | — |
| Steven Stein | Option | 27,629 | 68.25 | — |
| Thomas Tray | Option | 410 | 77.67 | — |
| Thomas Tray | Option | 433 | 83.2 | — |
| Thomas Tray | Option | 2,454 | 68.25 | — |
| Thomas Tray | Option | 1,665 | 61.76 | — |
| Thomas Tray | Option | 1,794 | 61.18 | — |
| Thomas Tray | Option | 2,444 | 64.25 | — |
| Thomas Tray | Option | 2,217 | 71.93 | — |
Incyte's compensation program is designed to attract and retain highly qualified directors and executives by aligning compensation with peer companies. It reflects the time, effort, expertise, and accountability required for active board and executive service.
| CEO STI target (% of salary) | 110% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-08 | 145,851,784 | 28,078,013 | 290,891 | 83.86% | Passed |
| 2025 | 2025-04-11 | 153,838,972 | 13,020,842 | 571,301 | 92.2% | Passed |
| 2024 | 2024-06-12 | 171,688,040 | 19,939,207 | 336,172 | 89.59% | Passed |
| 2023 | 2023-06-14 | 169,320,952 | 23,663,412 | 241,860 | 87.74% | Passed |
| 2022 | 2022-06-15 | 170,569,049 | 17,789,075 | 82,012 | 90.56% | Passed |
| 2021 | 2021-05-13 | 175,778,841 | 14,039,038 | 89,356 | 92.6% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-08 | 83.86%a |
| 2025 | 2025-04-11 | 92.2%b |
| 2024 | 2024-06-12 | 89.59%c |
a. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.
b. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.
c. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 110.47 : 1 |
|---|---|
| CEO total compensation | $32,688,692 |
| Median employee compensation | $295,914 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Julian C. BakerIndependent · Nominating and Corporate Governance (Chair) · Compensation | $0 | $308,436 | $264,702 | $0 | $0 | $573,138 |
| Edmund P. HarriganIndependent · Science and Technology (Chair) · Audit | 0 | 274,936 | 264,702 | 0 | 0 | 539,638 |
| Paul J. ClancyIndependent · Audit (Chair) · Compensation | 0 | 273,436 | 264,702 | 0 | 0 | 538,138 |
| Jean-Jacques BienaiméIndependent · Compensation (Chair) · Nominating and Corporate Governance | 95,000 | 176,436 | 264,702 | — | — | 536,138 |
| Jacqualyn A. FouseIndependent · Audit · Nominating and Corporate Governance | 83,500 | 176,436 | 264,702 | 0 | 0 | 524,638 |
| Susanne SchaffertIndependent · Compensation | 82,000 | 176,436 | 264,702 | 0 | 0 | 523,138 |
| Otis W. BrawleyIndependent · Science and Technology | 70,000 | 176,436 | 264,702 | 0 | 0 | 511,138 |
| Katherine A. HighIndependent · Science and Technology | 70,000 | 176,436 | 264,702 | 0 | 0 | 511,138 |
| William J. MeuryEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Hervé HoppenotEmployee director · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $65,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 / 20,000 |
| Stock ownership guideline | $390,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $400,500 |
| Equity awards (grant-date value) | $1,738,988 |
| All other compensation | $0 |
| Total cost of the board | $2,139,488 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies INCYTE CORP names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including INCYTE CORP.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | INCYTE CORP | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 4 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 5 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 7 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 8 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 9 | BeOne Medicines Ltd. | 2025 | John Oyler | 1,133,000 | 11,249,615 | 3,749,967 | 1,676,840 | 17,943,521 |
| 10 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 11 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 12 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 13 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| — | argenx SE | — | — | — | — | — | — | not in coverage universe |
| — | Genmab A/S | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| INCYTE CORP | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| argenx SE | not disclosed | not disclosed | not disclosed | not disclosed |
| BeOne Medicines Ltd. | 148% | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Genmab A/S | not disclosed | not disclosed | not disclosed | not disclosed |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, William Meury | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 2 | Section 01, Mohamed Issa | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 10,592,782. Filing ↗machine: span 660264–660274 |
| 3 | Section 01, Pablo Cagnoni | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 8,838,961. Filing ↗machine: r6 · c30 · span 650737–650746 |
| 4 | Section 01, Herve Hoppenot | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 6,380,525. Filing ↗machine: t91 · r3 · c16 · span 641487–641496 |
| 5 | Section 01, Steven Stein | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 6,304,172. Filing ↗machine: r10 · c30 · span 663627–663636 |
| 6 | Section 01, Christiana Stamoulis | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 4,936,550. Filing ↗machine: r13 · c30 · span 672876–672885 |
| 7 | Section 01, Thomas Tray | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Summary Compensation Table”. As printed: 990,368. Filing ↗machine: r16 · c30 · span 682687–682694 |
| 8 | Section 03, William Meury PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c23 · span 751118–751127 |
| 9 | Section 03, Thomas Tray PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r38 · c12 · span 827154–827159 |
| 10 | Section 03, Pablo Cagnoni OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r16 · c21 · span 775094–775101 |
| 11 | Section 03, Mohamed Issa PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r23 · c23 · span 791975–791984 |
| 12 | Section 03, Mohamed Issa PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r24 · c21 · span 794174–794181 |
| 13 | Section 03, Mohamed Issa RSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r20 · c21 · span 784652–784661 |
| 14 | Section 03, Christiana Stamoulis PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r34 · c21 · span 818355–818362 |
| 15 | Section 03, Steven Stein PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r28 · c23 · span 804062–804071 |
| 16 | Section 03, Christiana Stamoulis PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r33 · c23 · span 816155–816164 |
| 17 | Section 03, Hervé Hoppenot OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r10 · c21 · span 760644–760651 |
| 18 | Section 03, Hervé Hoppenot OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r9 · c21 · span 758279–758288 |
| 19 | Section 03, Hervé Hoppenot PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r13 · c21 · span 767961–767968 |
| 20 | Section 03, Hervé Hoppenot PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r12 · c23 · span 765762–765771 |
| 21 | Section 03, Mohamed Issa PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r21 · c21 · span 786852–786861 |
| 22 | Section 03, Steven Stein PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r29 · c21 · span 806262–806269 |
| 23 | Section 03, Mohamed Issa OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r22 · c15 · span 788325–788331 |
| 24 | Section 03, Thomas Tray OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r36 · c21 · span 823151–823157 |
| 25 | Section 03, William Meury PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r5 · c23 · span 748356–748366 |
| 26 | Section 03, Christiana Stamoulis OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r32 · c21 · span 813397–813404 |
| 27 | Section 03, Pablo Cagnoni PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r18 · c21 · span 780052–780061 |
| 28 | Section 03, William Meury RSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r7 · c21 · span 753317–753326 |
| 29 | Section 03, Pablo Cagnoni PSU | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r17 · c23 · span 777852–777861 |
| 30 | Section 03, Steven Stein OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r26 · c21 · span 798941–798948 |
| 31 | Section 03, William Meury OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r4 · c15 · span 744702–744709 |
| 32 | Section 03, Thomas Tray OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r37 · c21 · span 825512–825518 |
| 33 | Section 03, Christiana Stamoulis OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r31 · c21 · span 811034–811041 |
| 34 | Section 03, Steven Stein OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r27 · c21 · span 801304–801311 |
| 35 | Section 03, Pablo Cagnoni OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r15 · c21 · span 772731–772738 |
| 36 | Section 03, Hervé Hoppenot OPTION | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r11 · c21 · span 763007–763012 |
| 37 | Section 07, pay ratio | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “CEO Pay Ratio”. As printed: 110.47 : 1. Filing ↗machine: span 1232682–1232693 |
| 38 | Section 08, Julian C. Baker | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 573,138. Filing ↗machine: span 307703–307949 |
| 39 | Section 08, Edmund P. Harrigan | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 539,638. Filing ↗machine: span 316088–316333 |
| 40 | Section 08, Paul J. Clancy | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 538,138. Filing ↗machine: span 312735–312980 |
| 41 | Section 08, Jean-Jacques Bienaimé | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 536,138. Filing ↗machine: span 309389–309634 |
| 42 | Section 08, Jacqualyn A. Fouse | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 524,638. Filing ↗machine: span 314411–314656 |
| 43 | Section 08, Susanne Schaffert | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 523,138. Filing ↗machine: span 319870–320150 |
| 44 | Section 08, Otis W. Brawley | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 511,138. Filing ↗machine: span 311062–311307 |
| 45 | Section 08, Katherine A. High | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 511,138. Filing ↗machine: span 317763–318008 |
| 46 | Section 08, William J. Meury | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 47 | Section 08, Hervé Hoppenot | DEF 14A | 2026-04-28 | 0000879169-26-000031 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 48 | Section 02, Suketu Upadhyay 2026-05-04 | Form 4 | 2026-05-06 | 0001533149-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Suketu Upadhyay 2026-05-04 | Form 4 | 2026-05-06 | 0001533149-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Suketu Upadhyay 2026-05-04 | Form 4 | 2026-05-06 | 0001533149-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Steven Stein 2026-05-06 | Form 4 | 2026-05-20 | 0001673776-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Pablo Cagnoni 2026-05-06 | Form 4 | 2026-05-20 | 0001205703-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, BAKER BROS. ADVISORS LP 2026-05-08 | Form 4 | 2026-05-11 | 0001193125-26-216988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, BAKER BROS. ADVISORS LP 2026-05-08 | Form 4 | 2026-05-11 | 0001193125-26-216988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, BAKER BROS. ADVISORS LP 2026-05-08 | Form 4 | 2026-05-11 | 0001193125-26-216988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, BAKER BROS. ADVISORS LP 2026-05-08 | Form 4 | 2026-05-11 | 0001193125-26-216988 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Paul J. Clancy 2026-05-19 | Form 4 | 2026-05-21 | 0001409601-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Paul J. Clancy 2026-05-19 | Form 4 | 2026-05-21 | 0001409601-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Paul J. Clancy 2026-05-19 | Form 4 | 2026-05-21 | 0001409601-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Jean Jacques Bienaime 2026-05-26 | Form 4 | 2026-05-28 | 0001221590-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Jean Jacques Bienaime 2026-05-26 | Form 4 | 2026-05-28 | 0001221590-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Jean Jacques Bienaime 2026-05-26 | Form 4 | 2026-05-28 | 0001221590-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Thomas Tray 2026-05-26 | Form 4 | 2026-05-28 | 0001912317-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Pablo Cagnoni 2026-06-01 | Form 4 | 2026-06-03 | 0001205703-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Thomas Tray 2026-06-04 | Form 4 | 2026-06-08 | 0001912317-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Thomas Tray 2026-06-04 | Form 4 | 2026-06-08 | 0001912317-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Thomas Tray 2026-06-04 | Form 4 | 2026-06-08 | 0001912317-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Otis W. Brawley 2026-06-08 | Form 4 | 2026-06-10 | 0001213029-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Otis W. Brawley 2026-06-08 | Form 4 | 2026-06-10 | 0001213029-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Katherine A. High 2026-06-08 | Form 4 | 2026-06-10 | 0001631248-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Katherine A. High 2026-06-08 | Form 4 | 2026-06-10 | 0001631248-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Jean Jacques Bienaime 2026-06-08 | Form 4 | 2026-06-10 | 0001221590-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Jean Jacques Bienaime 2026-06-08 | Form 4 | 2026-06-10 | 0001221590-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Paul J. Clancy 2026-06-08 | Form 4 | 2026-06-10 | 0001409601-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Jacqualyn A. Fouse 2026-06-08 | Form 4 | 2026-06-10 | 0001405288-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Paul J. Clancy 2026-06-08 | Form 4 | 2026-06-10 | 0001409601-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Edmund P. Harrigan 2026-06-08 | Form 4 | 2026-06-10 | 0001177917-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, BAKER BROS. ADVISORS LP 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-265952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, BAKER BROS. ADVISORS LP 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-265952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, BAKER BROS. ADVISORS LP 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-265952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jacqualyn A. Fouse 2026-06-08 | Form 4 | 2026-06-10 | 0001405288-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Edmund P. Harrigan 2026-06-08 | Form 4 | 2026-06-10 | 0001177917-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, BAKER BROS. ADVISORS LP 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-265952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, BAKER BROS. ADVISORS LP 2026-06-30 | Form 4 | 2026-07-02 | 0001193125-26-294712 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, BAKER BROS. ADVISORS LP 2026-06-30 | Form 4 | 2026-07-02 | 0001193125-26-294712 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Paul J. Clancy 2026-06-30 | Form 4 | 2026-07-02 | 0001409601-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Edmund P. Harrigan 2026-06-30 | Form 4 | 2026-07-02 | 0001177917-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Steven Stein 2026-07-02 | Form 4 | 2026-07-07 | 0001673776-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, William Meury 2026-07-02 | Form 4 | 2026-07-07 | 0001536778-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Thomas Tray 2026-07-02 | Form 4 | 2026-07-07 | 0001912317-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Patrick A. Mayes 2026-07-02 | Form 4 | 2026-07-07 | 0002079962-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Steven Stein 2026-07-14 | Form 4 | 2026-07-16 | 0001673776-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Thomas Tray 2026-07-14 | Form 4 | 2026-07-16 | 0001912317-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Patrick A. Mayes 2026-07-14 | Form 4 | 2026-07-16 | 0002079962-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Pablo Cagnoni 2026-07-14 | Form 4 | 2026-07-16 | 0001205703-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Mohamed Issa 2026-07-15 | Form 4 | 2026-07-16 | 0002050035-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Steven Stein 2026-07-15 | Form 4 | 2026-07-16 | 0001673776-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Steven Stein 2026-07-15 | Form 4 | 2026-07-16 | 0001673776-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Patrick A. Mayes 2026-07-15 | Form 4 | 2026-07-16 | 0002079962-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Pablo Cagnoni 2026-07-15 | Form 4 | 2026-07-16 | 0001205703-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Thomas Tray 2026-07-15 | Form 4 | 2026-07-16 | 0001912317-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Pablo Cagnoni 2026-07-16 | Form 4 | 2026-07-20 | 0001205703-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Mohamed Issa 2026-07-16 | Form 4 | 2026-07-20 | 0002050035-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, William Meury 2026-07-16 | Form 4 | 2026-07-20 | 0001536778-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Richard A. Hoffman 2026-07-16 | Form 4 | 2026-07-20 | 0002098091-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Richard A. Hoffman 2026-07-16 | Form 4 | 2026-07-20 | 0002098091-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, David H. Gardner 2026-07-16 | Form 4 | 2026-07-20 | 0002085970-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Mohamed Issa 2026-07-16 | Form 4 | 2026-07-20 | 0002050035-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Pablo Cagnoni 2026-07-16 | Form 4 | 2026-07-20 | 0001205703-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Pablo Cagnoni 2026-07-16 | Form 4 | 2026-07-20 | 0001205703-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Steven Stein 2026-07-16 | Form 4 | 2026-07-20 | 0001673776-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Patrick A. Mayes 2026-07-16 | Form 4 | 2026-07-20 | 0002079962-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Steven Stein 2026-07-16 | Form 4 | 2026-07-20 | 0001673776-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Steven Stein 2026-07-16 | Form 4 | 2026-07-20 | 0001673776-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Thomas Tray 2026-07-16 | Form 4 | 2026-07-20 | 0001912317-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Thomas Tray 2026-07-16 | Form 4 | 2026-07-20 | 0001912317-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, William Meury 2026-07-16 | Form 4 | 2026-07-20 | 0001536778-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, David H. Gardner 2026-07-16 | Form 4 | 2026-07-20 | 0002085970-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Patrick A. Mayes 2026-07-16 | Form 4 | 2026-07-20 | 0002079962-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, William Meury 2026-07-16 | Form 4 | 2026-07-20 | 0001536778-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Richard A. Hoffman 2026-07-16 | Form 4 | 2026-07-20 | 0002098091-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Ramitpal K. Basi 2026-07-16 | Form 4 | 2026-07-20 | 0002083591-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Mohamed Issa 2026-07-16 | Form 4 | 2026-07-20 | 0002050035-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Steven Stein 2026-07-16 | Form 4 | 2026-07-20 | 0001673776-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Ramitpal K. Basi 2026-07-16 | Form 4 | 2026-07-20 | 0002083591-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Patrick A. Mayes 2026-07-16 | Form 4 | 2026-07-20 | 0002079962-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, David H. Gardner 2026-07-16 | Form 4 | 2026-07-20 | 0002085970-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Ramitpal K. Basi 2026-07-16 | Form 4 | 2026-07-20 | 0002083591-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Mohamed Issa 2026-07-16 | Form 4 | 2026-07-20 | 0002050035-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Lee Heeson 2026-07-23 | Form 4 | 2026-07-27 | 0002039219-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Lee Heeson 2026-07-23 | Form 4 | 2026-07-27 | 0002039219-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Michael James Morrissey 2026-07-23 | Form 4 | 2026-07-27 | 0001780915-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Michael James Morrissey 2026-07-23 | Form 4 | 2026-07-27 | 0001780915-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Pablo Cagnoni 2026-07-31 | Form 4 | 2026-08-04 | 0001205703-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Patrick A. Mayes 2026-07-31 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Patrick A. Mayes 2026-08-03 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Patrick A. Mayes 2026-08-03 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Patrick A. Mayes 2026-08-03 | Form 4 | 2026-08-04 | 0002079962-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Patrick A. Mayes 2026-08-05 | Form 4 | 2026-08-07 | 0002079962-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Patrick A. Mayes 2026-08-05 | Form 4 | 2026-08-07 | 0002079962-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Patrick A. Mayes 2026-08-05 | Form 4 | 2026-08-07 | 0002079962-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Pablo Cagnoni 2026-08-05 | Form 4 | 2026-08-07 | 0001205703-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Pablo Cagnoni 2026-08-12 | Form 4 | 2026-08-14 | 0001205703-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Pablo Cagnoni 2026-08-19 | Form 4 | 2026-08-20 | 0001205703-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Ramitpal K. Basi 2026-08-25 | Form 4 | 2026-08-27 | 0002083591-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Pablo Cagnoni 2026-09-15 | Form 4 | 2026-09-17 | 0001205703-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, David H. Gardner 2026-09-22 | Form 4 | 2026-09-24 | 0002085970-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Paul J. Clancy 2026-09-30 | Form 4 | 2026-10-02 | 0001409601-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Edmund P. Harrigan 2026-09-30 | Form 4 | 2026-10-02 | 0001177917-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, BAKER BROS. ADVISORS LP 2026-09-30 | Form 4 | 2026-10-02 | 0001193125-26-412653 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, BAKER BROS. ADVISORS LP 2026-09-30 | Form 4 | 2026-10-02 | 0001193125-26-412653 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Lee Heeson 2026-10-01 | Form 4 | 2026-10-05 | 0002039219-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Pablo Cagnoni 2026-10-15 | Form 4 | 2026-10-19 | 0001205703-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 06, 2026 vote | Form 8-K | 2026-06-09 | 0000879169-26-000043 | Item 5.07 · say-on-pay result. As reported: 83.86% (votes for as printed: 145,851,784). Filing ↗ |
| 212 | Section 06, 2025 vote | Form 8-K | 2025-06-11 | 0000879169-25-000062 | Item 5.07 · say-on-pay result. As reported: 92.2% (votes for as printed: 153,838,972). Filing ↗ |
| 213 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0000879169-24-000082 | Item 5.07 · say-on-pay result. As reported: 89.59% (votes for as printed: 171,688,040). Filing ↗ |
| 214 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 215 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 216 | Section 09b board cost (computed) | Computed | — | — | Cash 400,500 + equity 1,738,988 + all other 0 = 2,139,488, summed across the director compensation table rows.machine: formula: Σ = 2,139,488 |
| 217 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 218 | INCYTE CORP (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in INCYTE CORP's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 219 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 220 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗ |
| 221 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 222 | Moderna, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 223 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 224 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 225 | BeOne Medicines Ltd., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-049655 | CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021 |
| 226 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 227 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 228 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 229 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 230 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 231 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 232 | Section 10a, Moderna, Inc. reciprocity | DEF 14A | — | 0001308179-26-000081 | Moderna, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 233 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include INCYTE CORP. Filing ↗ |
| 234 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 235 | Section 10a, BeOne Medicines Ltd. reciprocity | DEF 14A | — | 0001104659-26-049655 | BeOne Medicines Ltd. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 236 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 237 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 238 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 239 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the INCYTE CORP Executive Compensation Report
$1,500